Class / Patent application number | Description | Number of patent applications / Date published |
536220100 |
N-glycosides, polymers thereof, metal derivatives (e.g., nucleic acids, oligonucleotides, etc.)
| 1505 |
536053000 |
Oxygen double bonded and nitrogen bonded directly to the same carbon
| 57 |
536020000 |
Chitin or derivative
| 41 |
536055000 |
Plural nitrogens containing
| 26 |
536030000 |
Cellulose derivatives
| 21 |
536021000 |
Heparin or derivative
| 21 |
536550300 |
Processes
| 17 |
536045000 |
Starch derivatives
| 17 |
536054000 |
Sulfur containing
| 14 |
536550200 |
Glucosamine containing
| 9 |
536051000 |
Dextran derivatives | 5 |
20120214978 | Reducing Non-Covalently Bound Polysaccharide On Supports - Methods and reagents are disclosed for reducing an amount of non-covalently bound polysaccharide on a support. The method comprises contacting a support comprising both covalently bound polysaccharide and non-covalently bound polysaccharide with an aqueous solution comprising an amount of a chaotropic agent effective to remove non-covalently bound polysaccharide from the support. | 08-23-2012 |
20120283427 | CATIONIC DEXTRAN POLYMER DERIVATIVES - Cationic dextran polymer derivatives including an ester-linked amine-containing substituent and an alkyl ester substituent and methods for making such dextran polymer derivatives are disclosed. | 11-08-2012 |
20130245246 | POLYSACCHARIDES COMPRISING CARBOXYL FUNCTIONAL GROUPS SUBSTITUTED BY A HYDROPHOBIC ALCOHOL DERIVATIVE - A polysaccharide comprising carboxyl functional groups, at least one of which is substituted with at least one hydrophobic radical:
| 09-19-2013 |
20160102154 | HYBRID COOPERATIVE COMPLEXES OF HYALURONIC ACID - Describes cooperative hybrid complexes of hyaluronic acid, a simple and economical method for production thereof and use thereof in the area of medicine, cosmetics and food. | 04-14-2016 |
20160251470 | ZWITTERIONIC POLYSACCHARIDE POLYMERS HAVING ANTIFOULING, ANTIMICROBIAL AND OPTICAL TRANSPARENCY PROPERTIES | 09-01-2016 |
536290200 |
C-glycosides wherein the sugar ring is bonded directly to carbon of an N-hetero ring (e.g., 9-deazaadenosines, etc.) | 4 |
20100216985 | STABLE CYSTAL OF PROTECTED PSEUDOURIDINE - A stable and high-purity protected pseudouridine in crystal form is provided represented by the following structural formula: | 08-26-2010 |
20110230654 | PROCESSES AND INTERMEDIATES FOR THE PREPARATION OF 1'-SUBSTITUTED CARBA-NUCLEOSIDE ANALOGS - Provided are processes and intermediates for the syntheses of nucleosides of pyrrolo[1,2-f][1,2,4]triazinyl and imidazo[1,24][1,2,4]triazinyl heterocycles of Formula I. | 09-22-2011 |
20150353594 | Protecting Groups For "Z Nucleotide" And Methods Thereof - The present disclosure provides a unique methodology and protecting groups that enable synthesis of oligonucleotides having Z nucleotide in an easy, clean and site-specific fashion with high yield. In particular, the method causes little to no damage to oligonucleotide product and does not modify the Z nucleotide itself. The invention provides a viable protection strategy for efficient synthesis of long oligonucleotides with Z nucleotide incorporated therein. | 12-10-2015 |
20160122356 | METHODS FOR THE PREPARATION OF RIBOSIDES - Provided are methods of preparing compounds and pharmaceutical compositions for treating Filoviridae virus infections The compounds, compositions, and methods provided are particularly useful for the treatment of Marburg virus, Ebola virus and Cueva virus infections. | 05-05-2016 |
Entries |
Document | Title | Date |
20090247738 | BIOCOMPATIBLE POLY-BETA-1-4-N-ACETYLGLUCOSAMINE - The present invention relates to a purified, easily produced poly-β-1→4-N-acetylglucosamine (p-GlcNAc) polysaccharide species. The p-GlcNAc of the invention is a polymer of high molecular weight whose constituent monosaccharide sugars are attached in a β-1→4 conformation, and which in free of proteins, and substantially free of single amino acids, and other organic and inorganic contaminants. In addition, derivatives and reformulations of p-GlcNAc are described. The present invention further relates to methods for the purification of the p-GlcNAc of the invention from microalgae, preferably diatom, starting sources. Still further, the invention relates to methods for the derivatization and reformulation of the p-GlcNAc. Additionally, the present invention relates to the uses of pure p-GlcNAc, its derivatives, and/or its reformulations. | 10-01-2009 |
20100249392 | Glucopyranosyl-substituted benzonitrile derivatives, pharmaceutical compositions containing such compounds, their use and process for their manufacture - Glucopyranosyl-substituted benzonitrile derivatives defined according to claim | 09-30-2010 |
20110112282 | IDO INHIBITORS AND THERAPEUTIC USES THEREOF - Compounds of formula (I), and pharmaceutically acceptable salts thereof, in which each compound is adapted to occupy the binding site of human IDO, which comprises a large hydrophobic pocket A and a second, proximal hydrophobic pocket B, the compound comprising at least one of the following elements: (i) a large hydrophobic fragment to substantially fill pocket A in the binding site of human IDO; (ii) an atom that can coordinate to the heme iron of human IDO, (iii) a positively charged group that can form a salt-bridge with the heme 7-propionate of the human IDO; (iv) a negatively charged group that can form a salt-bridge with Arg231 of the human IDO; (v) a hydrophobic group that can form van der Waals interactions with pocket B; and (vi) one or more substituents that can hydrogen bond to Ser167 and to Gly262, and as IDO inhibitors and their therapeutic use, eg in the treatment of cancer. | 05-12-2011 |
20110144317 | MUTANTS OF GLYCOSIDE HYDROLASES AND USES THEREOF FOR SYNTHESIZING COMPLEX OLIGOSACCHARIDES AND DISACCHARIDE INTERMEDIATES - Method for preparing the disaccharide [α-D-Gldp(1→3)]-α-L-Rhap-YR wherein Y is selected from —O— and —S— and R is selected from the group consisting of: C | 06-16-2011 |
20110190481 | EXTRACTION METHOD FOR SIALIC ACID-CONTAINING COMPOUND FROM PLANT - An object of the present invention is to provide an inexpensive and simple extraction method for a sialic acid-containing compound from a raw material which is easily available and has no risk of contamination with pathogens affecting animals (raw material which has high safety) without requiring the use of a reagent harmful to the human body and environment. The present invention is also aimed at providing an extraction method for a sialic acid-containing compound, the method comprising: crudely extracting a soluble component from a plant body (in particular, seeds of cereal and/or seeds of bean) or a processed product of the plant body with water, an alcohol, or an aqueous alcohol; and separating and recovering the sialic acid-containing compound from the resultant crude extract solution by dialysis, salt precipitation, or column chromatography. | 08-04-2011 |
20110218331 | Method of Preparation of DTPA Crosslinked Hyaluronic Acid Derivatives and Modification of Said Dervivatives - The invention relates to the modification of hyaluronic acid by means of a protonized DTPA bis anhydride in a non-basic polar aprotic solvent in absence of any external base to form crosslinked products. The reaction runs via the formation of a complex and the acylating agent is the hyaluronan co-cation itself, i.e. protonized DTPA bis anhydride. The final crosslinked derivative (linker) comprises three carboxylic groups and three tertiary amines which are capable of complexing various metals effectively. The final DTPA crosslinked hyaluronic acid may also be hydrophobized by means of mono, bis or tris functional alkylating agents. | 09-08-2011 |
20110237785 | SPATIALLY-DEFINED MACROCYCLIC COMPOUNDS USEFUL FOR DRUG DISCOVERY - Novel spatially-defined macrocyclic compounds containing specific conformational control elements are disclosed. Libraries of these macrocycles are then used to select one or more macrocycle species that exhibit a specific interaction with a particular biological target. In particular, compounds according to the invention are disclosed as agonists or antagonists of a mammalian motilin receptor and a mammalian ghrelin receptor. | 09-29-2011 |